Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Mirati Therapeutics price target raised to $56 from $52 at B. Riley » 07:48
01/23/23
01/23
07:48
01/23/23
07:48
MRTX

Mirati Therapeutics

$45.71 /

+2.58 (+5.98%)

B. Riley analyst Kalpit…

B. Riley analyst Kalpit Patel raised the firm's price target on Mirati Therapeutics to $56 from $52 and keeps a Neutral rating on the shares after the FDA cleared the Investigational New Drug application for MRTX1133. The analyst acknowledges the potential for robust Phase I data for MRTX1133 serves as a key risk to the firm's neutral thesis. However, it is unclear whether the drug can achieve plasma exposures required for such clinical activity, B. Riley tells investors in a research note.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$45.71 /

+2.58 (+5.98%)

MRTX Mirati Therapeutics
$45.71 /

+2.58 (+5.98%)

12/14/22 Needham
Mirati Therapeutics initiated with a Hold at Needham
12/14/22 Barclays
Mirati Therapeutics price target lowered to $90 from $169 at Barclays
12/13/22 Piper Sandler
Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
12/13/22 Piper Sandler
Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
MRTX Mirati Therapeutics
$45.71 /

+2.58 (+5.98%)

MRTX Mirati Therapeutics
$45.71 /

+2.58 (+5.98%)

MRTX Mirati Therapeutics
$45.71 /

+2.58 (+5.98%)

Hot Stocks
Mirati Therapeutics says FDA clears IND application of MRTX1133 » 17:01
01/19/23
01/19
17:01
01/19/23
17:01
MRTX

Mirati Therapeutics

$42.95 /

-1.76 (-3.94%)

Mirati Therapeutics…

Mirati Therapeutics announced the U.S. Food and Drug Administration has cleared the Investigational New Drug application of MRTX1133, a potential first-in-class oral KRASG12D selective inhibitor for clinical evaluation. KRASG12D mutations impact approximately 180,000 patients in the US and Europe, representing approximately a 2.5-fold increase in prevalence compared to KRASG12C mutations. No targeted oncology treatment options currently exist for these patients. MRTX1133 is a highly potent investigational inhibitor of the KRASG12D driver mutation and demonstrated selective and reversible inhibition of KRASG12D in both its active and inactive states. In addition, MRTX1133 administration resulted in marked tumor response in preclinical KRASG12D mutated pancreatic cancer models as well as lung and colorectal cancer models. MRTX1133 has demonstrated favorable properties including a low risk for off-target activity and drug interactions and a predicted human half-life of greater than 50 hours. "The clearance by the FDA to initiate clinical evaluation of MRTX1133, the third program in our KRAS franchise to enter clinical development, is illustrative of the innovative approach to drug discovery and demonstrates the best-in-class capabilities of the Mirati team. This particular mutation has been difficult to target, and we are confident in our novel oral formulation strategy, which we believe will enable near-complete target inhibition over the full dosing interval," said James Christensen, Ph.D. chief scientific officer, Mirati Therapeutics, Inc. "We are thrilled to advance MRTX1133 into clinical development and the potential to positively impact people living with KRASG12D-mutated cancers."

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$42.95 /

-1.76 (-3.94%)

MRTX Mirati Therapeutics
$42.95 /

-1.76 (-3.94%)

12/14/22 Needham
Mirati Therapeutics initiated with a Hold at Needham
12/14/22 Barclays
Mirati Therapeutics price target lowered to $90 from $169 at Barclays
12/13/22 Piper Sandler
Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
12/13/22 Piper Sandler
Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
MRTX Mirati Therapeutics
$42.95 /

-1.76 (-3.94%)

MRTX Mirati Therapeutics
$42.95 /

-1.76 (-3.94%)

MRTX Mirati Therapeutics
$42.95 /

-1.76 (-3.94%)

Over a month ago
On The Fly
Short Report: Bearish views reach record high on Silvergate, Mirati Therapeutics » 18:36
12/31/22
12/31
18:36
12/31/22
18:36
SI

Silvergate Capital

$17.39 /

+0.76 (+4.57%)

, MRTX

Mirati Therapeutics

$45.32 /

+2.65 (+6.21%)

, W

Wayfair

$32.89 /

-0.295 (-0.89%)

, CNK

Cinemark

$8.67 /

+0.025 (+0.29%)

, BGFV

Big 5 Sporting

$8.82 /

-0.165 (-1.84%)

, JANX

Janux Therapeutics

$13.09 /

-0.725 (-5.25%)

Welcome to this week’s…

ShowHide Related Items >><<
W Wayfair
$32.89 /

-0.295 (-0.89%)

SI Silvergate Capital
$17.39 /

+0.76 (+4.57%)

MRTX Mirati Therapeutics
$45.32 /

+2.65 (+6.21%)

JANX Janux Therapeutics
$13.09 /

-0.725 (-5.25%)

CNK Cinemark
$8.67 /

+0.025 (+0.29%)

SI Silvergate Capital
$17.39 /

+0.76 (+4.57%)

12/13/22 JPMorgan
Silvergate Capital price target lowered to $30 from $50 at JPMorgan
12/12/22 Wedbush
Silvergate Capital price target lowered to $30 from $45 at Wedbush
12/07/22 BTIG
Signature Bank crypto news opens window of opportunity for Silvergate, says BTIG
12/05/22 Morgan Stanley
Silvergate Capital downgraded to Underweight from Equal Weight at Morgan Stanley
MRTX Mirati Therapeutics
$45.32 /

+2.65 (+6.21%)

12/14/22 Needham
Mirati Therapeutics initiated with a Hold at Needham
12/14/22 Barclays
Mirati Therapeutics price target lowered to $90 from $169 at Barclays
12/13/22 Piper Sandler
Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
12/13/22 Piper Sandler
Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
W Wayfair
$32.89 /

-0.295 (-0.89%)

12/15/22 Wolfe Research
Wayfair initiated with a Peer Perform at Wolfe Research
12/13/22 Citi
Wayfair initiated with a Buy at Citi
11/30/22 Stephens
Wayfair five-day holiday sales report implies upside to consensus, says Stephens
11/21/22 Cowen
Cowen downgrades Wayfair on home consumer demand concerns
CNK Cinemark
$8.67 /

+0.025 (+0.29%)

12/21/22 Benchmark
Cinemark price target lowered to $17 from $22 at Benchmark
11/07/22 B. Riley
Cinemark price target lowered to $16 from $17 at B. Riley
10/27/22 Morgan Stanley
Cinemark price target lowered to $16 from $22 at Morgan Stanley
10/12/22 B. Riley
Cinemark price target lowered to $17 from $23 at B. Riley
BGFV Big 5 Sporting
$8.82 /

-0.165 (-1.84%)

03/02/22 Lake Street
Big 5 Sporting price target lowered to $28 from $31 at Lake Street
01/28/22 Sidoti
Big 5 Sporting initiated with a Buy at Sidoti
JANX Janux Therapeutics
$13.09 /

-0.725 (-5.25%)

11/14/22 William Blair
Janux Therapeutics initiated with an Outperform at William Blair
W Wayfair
$32.89 /

-0.295 (-0.89%)

SI Silvergate Capital
$17.39 /

+0.76 (+4.57%)

MRTX Mirati Therapeutics
$45.32 /

+2.65 (+6.21%)

JANX Janux Therapeutics
$13.09 /

-0.725 (-5.25%)

CNK Cinemark
$8.67 /

+0.025 (+0.29%)

BGFV Big 5 Sporting
$8.82 /

-0.165 (-1.84%)

W Wayfair
$32.89 /

-0.295 (-0.89%)

SI Silvergate Capital
$17.39 /

+0.76 (+4.57%)

MRTX Mirati Therapeutics
$45.32 /

+2.65 (+6.21%)

CNK Cinemark
$8.67 /

+0.025 (+0.29%)

W Wayfair
$32.89 /

-0.295 (-0.89%)

SI Silvergate Capital
$17.39 /

+0.76 (+4.57%)

MRTX Mirati Therapeutics
$45.32 /

+2.65 (+6.21%)

JANX Janux Therapeutics
$13.09 /

-0.725 (-5.25%)

CNK Cinemark
$8.67 /

+0.025 (+0.29%)

BGFV Big 5 Sporting
$8.82 /

-0.165 (-1.84%)

W Wayfair
$32.89 /

-0.295 (-0.89%)

SI Silvergate Capital
$17.39 /

+0.76 (+4.57%)

JANX Janux Therapeutics
$13.09 /

-0.725 (-5.25%)

CNK Cinemark
$8.67 /

+0.025 (+0.29%)

BGFV Big 5 Sporting
$8.82 /

-0.165 (-1.84%)

Hot Stocks
Mirati Therapeutics jumps 6% to $43.69 after adagrasib breakthrough designation  17:04
12/21/22
12/21
17:04
12/21/22
17:04
MRTX

Mirati Therapeutics

$41.42 /

+0.12 (+0.29%)

 
ShowHide Related Items >><<
MRTX Mirati Therapeutics
$41.42 /

+0.12 (+0.29%)

MRTX Mirati Therapeutics
$41.42 /

+0.12 (+0.29%)

12/14/22 Needham
Mirati Therapeutics initiated with a Hold at Needham
12/14/22 Barclays
Mirati Therapeutics price target lowered to $90 from $169 at Barclays
12/13/22 Piper Sandler
Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
12/13/22 Piper Sandler
Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
MRTX Mirati Therapeutics
$41.42 /

+0.12 (+0.29%)

MRTX Mirati Therapeutics
$41.42 /

+0.12 (+0.29%)

MRTX Mirati Therapeutics
$41.42 /

+0.12 (+0.29%)

Hot Stocks
Mirati Therapeutics gets FDA breakthrough therapy designation for adagrasib » 17:04
12/21/22
12/21
17:04
12/21/22
17:04
MRTX

Mirati Therapeutics

$41.42 /

+0.12 (+0.29%)

The company states:…

The company states: "Mirati Therapeutics announced that the FDA has granted BTD to adagrasib in combination with cetuximab in patients with KRASG12C-mutated, advanced CRC whose cancer has progressed following prior treatment with chemotherapy and an anti-VEGF therapy. This designation is supported by results from the Phase 1b cohort of the KRYSTAL-1 trial. The FDA program grants BTD to expedite the development and regulatory review of drugs that have demonstrated preliminary clinical evidence of a substantial improvement over available therapy in the treatment of patients with serious diseases on at least one clinically significant endpoint. In addition, today, the NEJM published findings from the ongoing multicohort KRYSTAL-1 Phase 1/2 study evaluating adagrasib as monotherapy or combined with cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer. These data reported promising clinical activity and demonstrated a favorable tolerability profile with reversible adverse events."

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$41.42 /

+0.12 (+0.29%)

MRTX Mirati Therapeutics
$41.42 /

+0.12 (+0.29%)

12/14/22 Needham
Mirati Therapeutics initiated with a Hold at Needham
12/14/22 Barclays
Mirati Therapeutics price target lowered to $90 from $169 at Barclays
12/13/22 Piper Sandler
Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
12/13/22 Piper Sandler
Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
MRTX Mirati Therapeutics
$41.42 /

+0.12 (+0.29%)

MRTX Mirati Therapeutics
$41.42 /

+0.12 (+0.29%)

MRTX Mirati Therapeutics
$41.42 /

+0.12 (+0.29%)

On The Fly
Sell these stocks now, proven algorithm says » 14:36
12/16/22
12/16
14:36
12/16/22
14:36
INM

InMed Pharmaceuticals

$1.81 /

-0.14 (-7.18%)

, MRTX

Mirati Therapeutics

$43.83 /

+1.33 (+3.13%)

, SE

Sea Limited

$54.57 /

-6.52 (-10.67%)

, TOST

Toast

$18.77 /

+0.015 (+0.08%)

, SHOP

Shopify

$35.85 /

-0.55 (-1.51%)

, EQX

Equinox Gold

$3.51 /

+0.03 (+0.86%)

, CFLT

Confluent

$22.87 /

-0.09 (-0.39%)

, XMTR

Xometry

$32.67 /

-1.62 (-4.72%)

, RADI

Radius Global Infrastructure

$12.09 /

-0.17 (-1.39%)

, PL

Planet Labs

$5.32 /

+0.37 (+7.47%)

, PSFE

Paysafe

$11.69 /

-0.26 (-2.18%)

, FREY

Freyr Battery

$10.36 /

-0.535 (-4.91%)

, VERV

Verve Therapeutics

$18.96 /

-0.6 (-3.07%)

, CCL

Carnival

$8.38 /

-0.275 (-3.18%)

, EVA

Enviva

$54.63 /

-1.645 (-2.92%)

, RXRX

Recursion Pharmaceuticals

$8.13 /

-0.33 (-3.90%)

, MAXR

Maxar Technologies

$51.49 /

+28.44 (+123.38%)

Here are this week's…

ShowHide Related Items >><<
XMTR Xometry
$32.67 /

-1.62 (-4.72%)

VERV Verve Therapeutics
$18.96 /

-0.6 (-3.07%)

TOST Toast
$18.77 /

+0.015 (+0.08%)

SHOP Shopify
$35.85 /

-0.55 (-1.51%)

SE Sea Limited
$54.57 /

-6.52 (-10.67%)

RXRX Recursion Pharmaceuticals
$8.13 /

-0.33 (-3.90%)

RADI Radius Global Infrastructure
$12.09 /

-0.17 (-1.39%)

PSFE Paysafe
$11.69 /

-0.26 (-2.18%)

PL Planet Labs
$5.32 /

+0.37 (+7.47%)

MRTX Mirati Therapeutics
$43.83 /

+1.33 (+3.13%)

MAXR Maxar Technologies
$51.49 /

+28.44 (+123.38%)

INM InMed Pharmaceuticals
$1.81 /

-0.14 (-7.18%)

FREY Freyr Battery
$10.36 /

-0.535 (-4.91%)

EVA Enviva
$54.63 /

-1.645 (-2.92%)

EQX Equinox Gold
$3.51 /

+0.03 (+0.86%)

CFLT Confluent
$22.87 /

-0.09 (-0.39%)

CCL Carnival
$8.38 /

-0.275 (-3.18%)

INM InMed Pharmaceuticals
$1.81 /

-0.14 (-7.18%)

05/16/22 Roth MKM
InMed Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
MRTX Mirati Therapeutics
$43.83 /

+1.33 (+3.13%)

12/14/22 Needham
Mirati Therapeutics initiated with a Hold at Needham
12/14/22 Barclays
Mirati Therapeutics price target lowered to $90 from $169 at Barclays
12/13/22 Piper Sandler
Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
12/13/22 Piper Sandler
Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
SE Sea Limited
$54.57 /

-6.52 (-10.67%)

11/21/22 Cowen
Sea Limited downgraded on lack of visibility at Cowen
11/21/22 Cowen
Sea Limited downgraded to Market Perform from Outperform at Cowen
11/17/22 Morgan Stanley
Sea Limited price target lowered to $95 from $116 at Morgan Stanley
11/16/22 Cowen
Sea Limited price target lowered to $72 from $78 at Cowen
TOST Toast
$18.77 /

+0.015 (+0.08%)

12/16/22 Wells Fargo
Wells Fargo sees significant opportunity ahead for Toast
12/12/22 Mizuho
Fiserv price target lowered to $135 from $145 at Mizuho
11/29/22 Wolfe Research
Toast initiated with a Peer Perform at Wolfe Research
11/11/22 Needham
Toast price target raised to $32 from $27 at Needham
SHOP Shopify
$35.85 /

-0.55 (-1.51%)

12/09/22 SMBC Nikko
Shopify price target raised to $45 from $40 at SMBC Nikko
12/08/22 Capital One
Shopify initiated with an Equalweight at Capital One
12/08/22 UBS
Shopify initiated with a Sell at UBS
12/08/22 Mizuho
Shopify price target raised to $40 from $33 at Mizuho
EQX Equinox Gold
$3.51 /

+0.03 (+0.86%)

12/07/22 National Bank
Equinox Gold price target raised to C$5.50 from C$5 at National Bank
12/07/22 BMO Capital
Equinox Gold price target raised to C$6.50 from C$6 at BMO Capital
11/07/22 BMO Capital
Equinox Gold price target lowered to C$6 from C$7.50 at BMO Capital
11/04/22 National Bank
Equinox Gold price target lowered to C$4 from C$5 at National Bank
CFLT Confluent
$22.87 /

-0.09 (-0.39%)

11/03/22 DA Davidson
Confluent price target lowered to $33 from $44 at DA Davidson
11/03/22 Credit Suisse
Confluent price target lowered to $55 from $65 at Credit Suisse
11/03/22 Barclays
Confluent price target lowered to $27 from $30 at Barclays
11/01/22 Citi
Confluent price target lowered to $30 from $32 at Citi
XMTR Xometry
$32.67 /

-1.62 (-4.72%)

12/14/22 Lake Street
Xometry initiated with a Sell at Lake Street
12/13/22 Citi
Xometry initiated with a Buy at Citi
11/11/22 UBS
Xometry price target lowered to $45 from $55 at UBS
08/24/22 JPMorgan
JPMorgan cuts Xometry target but still sees 46% upside potential
RADI Radius Global Infrastructure
$12.09 /

-0.17 (-1.39%)

12/16/22 RBC Capital
Radius Global Infrastructure initiated with a Sector Perform at RBC Capital
12/14/22 Exane BNP Paribas
Radius Global Infrastructure initiated with an Outperform at Exane BNP Paribas
10/04/22 Raymond James
Radius Global Infrastructure price target lowered to $17 from $21 at Raymond James
05/10/22 Raymond James
Radius Global Infrastructure price target raised to $22 from $18 at Raymond James
PL Planet Labs
$5.32 /

+0.37 (+7.47%)

11/08/22 Deutsche Bank
Planet Labs initiated with a Buy at Deutsche Bank
09/13/22 Needham
Planet Labs price target raised to $9 from $8 at Needham
06/15/22 Craig-Hallum
Planet Labs price target lowered to $10 from $15 at Craig-Hallum
06/15/22 Needham
Planet Labs price target lowered to $8.00 from $10.50 at Needham
PSFE Paysafe
$11.69 /

-0.26 (-2.18%)

08/31/22 Susquehanna
Susquehanna downgrades Paysafe after CFO change, prefers to 'wait and see'
08/31/22 Susquehanna
Paysafe downgraded to Neutral from Positive at Susquehanna
08/11/22 Credit Suisse
Paysafe downgraded to Underperform from Neutral at Credit Suisse
08/10/22 RBC Capital
Paysafe downgraded to Sector Perform from Outperform at RBC Capital
FREY Freyr Battery
$10.36 /

-0.535 (-4.91%)

10/31/22 Cowen
Cowen starts Freyr Battery at Outperform, sees 'less technology risk'
10/31/22 Cowen
Freyr Battery initiated with an Outperform at Cowen
09/21/22 Morgan Stanley
Freyr Battery price target raised to $26, named a 'Top Pick' at Morgan Stanley
09/01/22 BTIG
Freyr Battery price target raised to $25 from $20 at BTIG
VERV Verve Therapeutics
$18.96 /

-0.6 (-3.07%)

12/15/22 Goldman Sachs
Verve Therapeutics initiated with a Sell at Goldman Sachs
12/05/22 Stifel
Verve FDA request 'provides fodder for both bulls and bears,' says Stifel
12/02/22 Guggenheim
Beam hold being lifted 'encouraging' for Verve Therapeutics, says Guggenheim
10/06/22 Credit Suisse
Verve Therapeutics initiated with a Neutral at Credit Suisse
CCL Carnival
$8.38 /

-0.275 (-3.18%)

12/15/22 Barclays
Carnival price target raised to $12 from $10 at Barclays
12/14/22 Stifel
Carnival price target raised to $18 at Stifel, would buy ahead of Q4 report
12/12/22 Credit Suisse
Credit Suisse keeps Outperform on Carnival, lowers price target to $19
12/06/22 JPMorgan
Carnival assumed with a Neutral at JPMorgan
EVA Enviva
$54.63 /

-1.645 (-2.92%)

11/29/22 RBC Capital
Enviva price target lowered to $63 from $76 at RBC Capital
10/20/22 JPMorgan
Enviva price target lowered to $60 from $66 at JPMorgan
10/18/22 Raymond James
Enviva upgraded to Strong Buy from Outperform at Raymond James
10/14/22 Citi
Citi upgrades Enviva to Buy, says short report selloff overdone
RXRX Recursion Pharmaceuticals
$8.13 /

-0.33 (-3.90%)

09/15/22 KeyBanc
Recursion Pharmaceuticals initiated with an Overweight at KeyBanc
04/18/22 BofA
Recursion Pharmaceuticals downgraded to Neutral from Buy at BofA
03/04/22 SVB Securities
Recursion Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
MAXR Maxar Technologies
$51.49 /

+28.44 (+123.38%)

12/16/22 Wells Fargo
Maxar Technologies downgraded to Equal Weight from Overweight at Wells Fargo
12/16/22 Canaccord
Maxar Technologies downgraded to Hold from Buy at Canaccord
12/16/22 Truist
Maxar Technologies downgraded to Hold from Buy at Truist
11/23/22 Truist
Maxar Technologies price target lowered to $37 from $44 at Truist
XMTR Xometry
$32.67 /

-1.62 (-4.72%)

VERV Verve Therapeutics
$18.96 /

-0.6 (-3.07%)

TOST Toast
$18.77 /

+0.015 (+0.08%)

SHOP Shopify
$35.85 /

-0.55 (-1.51%)

SE Sea Limited
$54.57 /

-6.52 (-10.67%)

RXRX Recursion Pharmaceuticals
$8.13 /

-0.33 (-3.90%)

RADI Radius Global Infrastructure
$12.09 /

-0.17 (-1.39%)

PSFE Paysafe
$11.69 /

-0.26 (-2.18%)

PL Planet Labs
$5.32 /

+0.37 (+7.47%)

MRTX Mirati Therapeutics
$43.83 /

+1.33 (+3.13%)

MAXR Maxar Technologies
$51.49 /

+28.44 (+123.38%)

INM InMed Pharmaceuticals
$1.81 /

-0.14 (-7.18%)

FREY Freyr Battery
$10.36 /

-0.535 (-4.91%)

EVA Enviva
$54.63 /

-1.645 (-2.92%)

EQX Equinox Gold
$3.51 /

+0.03 (+0.86%)

CFLT Confluent
$22.87 /

-0.09 (-0.39%)

CCL Carnival
$8.38 /

-0.275 (-3.18%)

  • 01
    Dec
  • 21
    Jul
  • 21
    Jul
  • 20
    Jan
  • 04
    Jan
SHOP Shopify
$35.85 /

-0.55 (-1.51%)

SE Sea Limited
$54.57 /

-6.52 (-10.67%)

RADI Radius Global Infrastructure
$12.09 /

-0.17 (-1.39%)

MRTX Mirati Therapeutics
$43.83 /

+1.33 (+3.13%)

EVA Enviva
$54.63 /

-1.645 (-2.92%)

CCL Carnival
$8.38 /

-0.275 (-3.18%)

XMTR Xometry
$32.67 /

-1.62 (-4.72%)

VERV Verve Therapeutics
$18.96 /

-0.6 (-3.07%)

TOST Toast
$18.77 /

+0.015 (+0.08%)

SHOP Shopify
$35.85 /

-0.55 (-1.51%)

SE Sea Limited
$54.57 /

-6.52 (-10.67%)

RXRX Recursion Pharmaceuticals
$8.13 /

-0.33 (-3.90%)

RADI Radius Global Infrastructure
$12.09 /

-0.17 (-1.39%)

PSFE Paysafe
$11.69 /

-0.26 (-2.18%)

PL Planet Labs
$5.32 /

+0.37 (+7.47%)

MRTX Mirati Therapeutics
$43.83 /

+1.33 (+3.13%)

MAXR Maxar Technologies
$51.49 /

+28.44 (+123.38%)

INM InMed Pharmaceuticals
$1.81 /

-0.14 (-7.18%)

FREY Freyr Battery
$10.36 /

-0.535 (-4.91%)

EVA Enviva
$54.63 /

-1.645 (-2.92%)

EQX Equinox Gold
$3.51 /

+0.03 (+0.86%)

CFLT Confluent
$22.87 /

-0.09 (-0.39%)

CCL Carnival
$8.38 /

-0.275 (-3.18%)

TOST Toast
$18.77 /

+0.015 (+0.08%)

SHOP Shopify
$35.85 /

-0.55 (-1.51%)

SE Sea Limited
$54.57 /

-6.52 (-10.67%)

PSFE Paysafe
$11.69 /

-0.26 (-2.18%)

PL Planet Labs
$5.32 /

+0.37 (+7.47%)

FREY Freyr Battery
$10.36 /

-0.535 (-4.91%)

EQX Equinox Gold
$3.51 /

+0.03 (+0.86%)

CFLT Confluent
$22.87 /

-0.09 (-0.39%)

CCL Carnival
$8.38 /

-0.275 (-3.18%)

Initiation
Mirati Therapeutics initiated with a Hold at Needham » 07:27
12/14/22
12/14
07:27
12/14/22
07:27
MRTX

Mirati Therapeutics

$41.98 /

+0.68 (+1.65%)

Needham analyst Ami Fadia…

Needham analyst Ami Fadia initiated coverage of Mirati Therapeutics with a Hold rating and no price target. Despite the recent pullback, Fadia struggles to see a path to near-term upside, the analyst tells investors in a research note. Last week's ESMO update puts into question adagrasib's likelihood of success in 1L NSCLC, particularly in TPS greater than or equal to 1%, the analyst adds.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$41.98 /

+0.68 (+1.65%)

MRTX Mirati Therapeutics
$41.98 /

+0.68 (+1.65%)

12/14/22 Barclays
Mirati Therapeutics price target lowered to $90 from $169 at Barclays
12/13/22 Piper Sandler
Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
12/13/22 Piper Sandler
Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
MRTX Mirati Therapeutics
$41.98 /

+0.68 (+1.65%)

MRTX Mirati Therapeutics
$41.98 /

+0.68 (+1.65%)

MRTX Mirati Therapeutics
$41.98 /

+0.68 (+1.65%)

Recommendations
Mirati Therapeutics price target lowered to $90 from $169 at Barclays » 06:01
12/14/22
12/14
06:01
12/14/22
06:01
MRTX

Mirati Therapeutics

$41.98 /

+0.68 (+1.65%)

Barclays analyst Gena…

Barclays analyst Gena Wang lowered the firm's price target on Mirati Therapeutics to $90 from $169 and keeps an Overweight rating on the shares. The company received Krazati accelerated approval and the label is largely consistent with Amgen's Lumakras, Wang tells investors in a research note. The analyst expects a gradual uptake given its second to market status, and believes a differentiated profile could lead to greater market share in the longer-term. She dropped the price target to reflect Mirati's recent updates.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$41.98 /

+0.68 (+1.65%)

MRTX Mirati Therapeutics
$41.98 /

+0.68 (+1.65%)

12/13/22 Piper Sandler
Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
12/13/22 Piper Sandler
Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
12/09/22 Stifel
Stifel cuts Mirati price target to $73, says move lower 'overdone'
12/09/22 Citi
Mirati Therapeutics downgraded to Neutral from Buy at Citi (yesterday)
MRTX Mirati Therapeutics
$41.98 /

+0.68 (+1.65%)

MRTX Mirati Therapeutics
$41.98 /

+0.68 (+1.65%)

MRTX Mirati Therapeutics
$41.98 /

+0.68 (+1.65%)

Recommendations
Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler » 20:53
12/13/22
12/13
20:53
12/13/22
20:53
MRTX

Mirati Therapeutics

$41.98 /

+0.68 (+1.65%)

Piper Sandler analyst…

Piper Sandler analyst Swapnil Malekar lowered the firm's price target on Mirati Therapeutics to $68 from $87 but keeps an Overweight rating on the shares. Mirati Therapeutics priced Krazati at a slight premium vs Lumakras and justified the overage based on advantage seen in CNSmet patients and a better safety profile, but he remains cautious until this theory pans out in the real world given the brain-met language or the safety data from tablet formulation was not reflected in the label, the analyst tells investors in a research note.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$41.98 /

+0.68 (+1.65%)

MRTX Mirati Therapeutics
$41.98 /

+0.68 (+1.65%)

12/13/22 Piper Sandler
Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
12/09/22 Stifel
Stifel cuts Mirati price target to $73, says move lower 'overdone'
12/09/22 Citi
Mirati Therapeutics downgraded to Neutral from Buy at Citi (yesterday)
12/08/22 BofA
Mirati Therapeutics price target lowered to $61 from $100 at BofA
MRTX Mirati Therapeutics
$41.98 /

+0.68 (+1.65%)

MRTX Mirati Therapeutics
$41.98 /

+0.68 (+1.65%)

MRTX Mirati Therapeutics
$41.98 /

+0.68 (+1.65%)

Recommendations
Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler » 04:36
12/13/22
12/13
04:36
12/13/22
04:36
MRTX

Mirati Therapeutics

$41.30 /

-0.4 (-0.96%)

Piper Sandler analyst…

Piper Sandler analyst Swapnil Malekar raised the firm's price target on Mirati Therapeutics to $87 from $84 and keeps an Overweight rating on the shares. The company received FDA approval for Krazati with the label language in line with the efficacy seen in the K-1 study, Malekar tells investors in a research note. The analyst views the overall label language to be largely similar to Lumakras and believes that the risk/benefit profile of the two drugs is identical.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$41.30 /

-0.4 (-0.96%)

MRTX Mirati Therapeutics
$41.30 /

-0.4 (-0.96%)

12/09/22 Stifel
Stifel cuts Mirati price target to $73, says move lower 'overdone'
12/09/22 Citi
Mirati Therapeutics downgraded to Neutral from Buy at Citi (yesterday)
12/08/22 BofA
Mirati Therapeutics price target lowered to $61 from $100 at BofA
12/08/22 JPMorgan
Mirati Therapeutics downgraded to Neutral from Overweight at JPMorgan
MRTX Mirati Therapeutics
$41.30 /

-0.4 (-0.96%)

MRTX Mirati Therapeutics
$41.30 /

-0.4 (-0.96%)

MRTX Mirati Therapeutics
$41.30 /

-0.4 (-0.96%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.